FIELD: biotechnology.
SUBSTANCE: described is a group of inventions involving the use of a combination of antibody molecules for treating cancer in a patient having tumor-infiltrating T-lymphocytes with medium or high PD-1 expression, use of a pharmaceutical composition for treating cancer in a patient, a kit for use in treating cancer in a patient, using a first antibody molecule which specifically binds FcγRIIb, and a second antibody molecule, which specifically binds PD-1 and which binds to at least one Fcγ receptor, when producing a medicament for use in treating cancer in a patient, a method for treating cancer in a patient, a diagnostic test for determining the patient’s benefit from a combination therapy, a combination of antibody molecules for treating cancer in a patient and a pharmaceutical composition for treating cancer in a patient.
EFFECT: invention extends the range of agents for treating cancer in a patient with tumor-infiltrating T-lymphocytes with medium or high PD-1 expression.
31 cl, 9 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BIOLOGICAL MATERIALS AND THEIR APPLICATION METHODS | 2011 |
|
RU2769949C2 |
| ANTI-C10orf54 ANTIBODIES AND APPLICATIONS THEREOF | 2015 |
|
RU2819627C1 |
| IMPROVED SINGLE VARIABLE IMMUNOGLOBULIN DOMAINS BINDING TO SERUM ALBUMIN | 2017 |
|
RU2765384C2 |
| PROGRAMMED CELL DEATH (PD-1) PROTEIN-1 ANTIBODIES AND USE THEREOF | 2017 |
|
RU2725950C1 |
| ANTIBODIES AGAINST LIGAND-1 PROGRAMMED DEATH (PD-L1) AND APPLICATION THEREOF | 2017 |
|
RU2721582C1 |
| ANTIBODIES AGAINST PD-L1 AND THEIR OPTIONS | 2017 |
|
RU2770590C2 |
| METHOD FOR TREATMENT OR PREVENTION OF STROKE | 2015 |
|
RU2744909C2 |
| HYBRID PROTEINS OF sPD-1-Fc VARIANT | 2019 |
|
RU2785993C2 |
| COMBINATION OF PD-1 ANTAGONIST AND ERIBULIN FOR TREATING CANCER | 2016 |
|
RU2737216C2 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732591C2 |
